- Home
- PCRX vs LEU Comparison
PCRX vs LEU Comparison
Compare PCRX & LEU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCRX
- LEU
- Stock Information
- Founded
- PCRX 2006
- LEU 1998
- Country
- PCRX United States
- LEU United States
- Employees
- PCRX N/A
- LEU 322
- Industry
- PCRX Biotechnology: Pharmaceutical Preparations
- LEU Mining & Quarrying of Nonmetallic Minerals (No Fuels)
- Sector
- PCRX Health Care
- LEU Industrials
- Exchange
- PCRX Nasdaq
- LEU Nasdaq
- Market Cap
- PCRX 1.2B
- LEU 3.1B
- IPO Year
- PCRX 2011
- LEU 1998
- Fundamental
- Price
- PCRX $23.22
- LEU $183.45
- Analyst Decision
- PCRX Buy
- LEU Buy
- Analyst Count
- PCRX 8
- LEU 9
- Target Price
- PCRX $28.38
- LEU $165.63
- AVG Volume (30 Days)
- PCRX 538.4K
- LEU 1.4M
- Earning Date
- PCRX 07-29-2025
- LEU 08-05-2025
- Dividend Yield
- PCRX N/A
- LEU N/A
- EPS Growth
- PCRX N/A
- LEU 40.85
- EPS
- PCRX N/A
- LEU 6.39
- Revenue
- PCRX $702,772,000.00
- LEU $471,400,000.00
- Revenue This Year
- PCRX $7.54
- LEU $3.22
- Revenue Next Year
- PCRX $10.78
- LEU $9.91
- P/E Ratio
- PCRX N/A
- LEU $28.72
- Revenue Growth
- PCRX 3.08
- LEU 58.72
- 52 Week Low
- PCRX $11.16
- LEU $33.51
- 52 Week High
- PCRX $27.64
- LEU $211.31
- Technical
- Relative Strength Index (RSI)
- PCRX 35.43
- LEU 64.96
- Support Level
- PCRX $22.82
- LEU $164.91
- Resistance Level
- PCRX $24.36
- LEU $184.43
- Average True Range (ATR)
- PCRX 0.70
- LEU 16.12
- MACD
- PCRX -0.10
- LEU -2.71
- Stochastic Oscillator
- PCRX 17.09
- LEU 53.81
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
About LEU Centrus Energy Corp.
Centrus Energy Corp is engaged in the supply of nuclear fuel and services for the nuclear power industry. It operates through the Low-Enriched Uranium (LEU) and Technical Solutions segments. The LEU segment has two components which include the sale of separative work units and uranium. The Technical Solutions segment provides engineering, design, and manufacturing services to government and private sector customers. The majority of the firm's revenue is derived from the LEU segment. It has a business presence in the U.S. and other countries, of which prime revenue is generated in the U.S.